Background In animal models of ischaemic stroke, 25% albumin reduced brain infarction and improved neurobehavioural outcome. In a pilot clinical trial, albumin doses as high as 2 g/kg were safely tolerated. We aimed to assess whether albumin given within 5 h of the onset of acute ischaemic stroke increased the proportion of patients with a favourable outcome.
Introduction
Stroke is the fourth leading cause of death in North America, the second leading cause of death globally, and a major cause of disability. 1 By 2030, stroke prevalence in the USA is projected to reach 4%, and stroke-related disability is estimated to become the fourth most important cause of disability-adjusted life years in developed countries. 2 In developing countries, stroke incidence has increased in the past few decades, and rates of disability and mortality in medically underserved regions are at least ten times greater than those in developed countries. 3 Roughly 80% of all strokes are ischaemic. 4 The only specifi c treatment shown to improve outcome in patients with acute ischaemic stroke is intravenous alteplase (tissue plasminogen activator, tPA), but the therapeutic benefi t of this treatment declines sharply in the fi rst few hours after stroke onset. 5 Preclinical studies 6 have implicated the contribution of various injurious biochemical, molecular, and vascular events in ischaemic brain injury, and have shown that the ischaemic brain could be protected by strategies designed to counteract these injury mechanisms. However, so far, translation of these approaches into treatment methods for patients with ischaemic stroke has been disappointing. 7, 8 In experimental studies 9,10 of acute ischaemic stroke, high doses of 25% human albumin have been consistently neuroprotective by reducing the volume of brain infarction, diminishing cerebral oedema, and improving behavioural function, with a therapeutic window of effi cacy of at least 4 h after stroke onset. 9, 10 Albumin improved perfusion to the ischaemic penumbra, 11 normalised the apparent diff usion coeffi cient within the residual infarct, 9 reversed stagnation in post-ischaemic cortical venules, 12 and improved microvascular haemodynamics distal to an arterial thrombosis. [13] [14] [15] In a pilot safety trial 10 in 82 individuals with acute ischaemic stroke, 25% albumin given in doses encompassing the neuroprotective range shown in experimental studies was tolerated with no major complications, and an exploratory analysis suggested possible effi cacy. 16, 17 In July, 2006, we began the randomised, multicentre Albumin in Acute Stroke (ALIAS) effi cacy trial 18 to assess whether 25% albumin treatment given within 5 h of the onset of acute ischaemic stroke would confer neurological and functional benefi t. After 434 participants had been enrolled, the Data and Safety Monitoring Board (DSMB) suspended further enrolment for safety reasons. An unmasked safety analysis of that trial (termed ALIAS part 1) showed that more patients died in the fi rst 30 days in the albumin group than in the placebo group, with patients older than 83 years mostly aff ected. Deaths were also increased in patients in the albumin group who had received excessive intravenous fl uids. We modifi ed the study design on the basis of these safety fi ndings and, with frequent supervision from the DSMB, we restarted the trial as ALIAS part 2 to identify whether a weightadjusted intravenous infusion of 25% albumin within 5 h of stroke onset would increase the proportion of patients with a favourable outcome at 90 days compared with those given isotonic saline. Here we report the results of ALIAS part 2.
Methods

Study design and participants
We undertook this multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial between Feb 27, 2009, and Sept 10, 2012, at 69 sites in the USA, 13 sites in Canada, two sites in Finland, and fi ve sites in Israel. Panel 1 lists the inclusion and exclusion criteria. A noncontrast CT or an MRI scan was required to exclude intracranial haemorrhage. Standard-of-care thrombolytic therapy was permitted and consisted of intravenous alteplase, intra-arterial alteplase, or endovascular thrombolysis with approved devices and catheters, on the basis of local clinical judgment. Endovascular procedures, if used, had to begin within 5 h and be completed within 7 h of stroke onset.
Human albumin 25% solution was manufactured for the trial and prepared in glass bottles by Baxter Healthcare (Westlake Village, CA, USA). Isotonic saline in glass bottles was purchased commercially. Study-drug kits were assembled and distributed to the sites by the US Department of Health and Human Services, Supply Service Center (Perry Point, MD, USA). Approval was obtained from an Institutional Review Board or Research Ethics Board at each study site. A DSMB appointed by the National Institute of Neurological Disorders and Stroke (NINDS) oversaw the safety and performance of the trial. Safety events were adjudicated by two independent medical monitors. We acquired an investigational new drug application with the US Food and Drug Administration and a Clinical Trial Application at Health Canada. Written informed consent was obtained from the patient or a legal representative before enrolment. The study protocol is available online.
Randomisation and masking
Patients were randomly assigned in a 1:1 ratio via a centralised web-based randomisation process to either 25% albumin solution (2 g/kg estimated bodyweight) or saline, with a biased coin minimisation approach that accounted for the status of treatment group balance within and across sites. 19 The time of randomisation was defi ned as the time at which the study-drug kit was unsealed. In patients who received intravenous alteplase, infusion of study drug needed to begin within 90 min after the start of alteplase. All study personnel and patients were masked to the identity of the study drug. Each sealed kit contained two bottles (initially of 500 mL and 250 mL, then, for manufacturing reasons, both of 500 mL) of the same substance (either albumin or saline) encased in cardboard blinding boxes similar to those used in the Saline versus Albumin Fluid Evaluation (SAFE) Trial, 20 in addition to fi lters and opaque sheathing to conceal the intravenous tubing.
Procedures
The primary endpoint was favourable outcome at 90 days after randomisation, defi ned as either a modifi ed Rankin scale (mRS) score of 0 or 1 or a National Institutes of Health stroke scale (NIHSS) score of 0 or 1, or both. The mRS ranges from 0 to 6, with higher scores denoting greater disability; scores of 0 or 1 denote absence of any functional disability. The NIHSS score ranges from 0 to 42; a score of 0 suggests a normal neurological examination and a score of 1 suggests negligible abnormality. A bedside nurse or other personnel not associated with the trial administered the study drug (8 mL/kg estimated bodyweight) by constant intravenous infusion over 2 h (plus or minus 15 min). Participants weighing 94 kg or more were given 750 mL. Vital signs were monitored frequently. Serum chemistry was collected at 24 h and 48 h. Intravenous fl uid intake was recorded at 24 h and 48 h. A follow-up brain CT or MRI scan was obtained at 24 h. An electrocardiogram (ECG) was repeated at 24-48 h. We assessed neurological and cardiac status, including NIHSS score, at 24 h and 48 h, and at 7 days or discharge, whichever came fi rst.
Intravenous fl uid management and diuretic administration were mandated. Patients were not to receive total intravenous fl uids in excess of 4200 mL during the fi rst 48 h, including the volumes of study drug and thrombolytic drug (if used). For patients exceeding For study protocol see https:// dcu.musc.edu/Projects/ MajorProjects.asp this amount, investigators had to provide justifi cations, which were centrally adjudicated on the basis of clinical reasonableness. Patients were also required to receive at least one dose of furosemide, 20 mg intravenously (or an equivalent loop diuretic), between 12 h and 24 h after administration of study drug. Physicians withholding diuretics were asked to provide a written justifi cation. Antiplatelet therapy was recommended in all patients within 48 h of their stroke. Blood pressure was managed according to the local standard of care.
Patients were followed up for 1 year. 90 days (plus or minus 30 days) after randomisation, participants were assessed in person on the NIHSS, mRS, Barthel index, stroke-specifi c quality-of-life scale, 21 and trailmaking A and B tests, 22 administered by a certifi ed and masked site investigator. Participants were also followed up by telephone contact at 1 month (plus or minus 7 days), 6 months (plus or minus 14 days), 9 months (plus or minus 14 days), and 1 year (plus or minus 14 days) after randomisation, to assess the mRS, record serious adverse events, and complete the EuroQol 23, 24 (at 3 months and 1 year) and the questionnaire to validate a stroke-free status 25 (at 3, 6, 9, and 12 months).
Statistical analysis
The study cohort consisted of patients not receiving thrombolysis and those who did receive thrombolysis (defi ned as any intravenous or endovascular thrombolytic or thrombectomy procedures). On the basis of simulation, the total required sample size was 1100, to yield 84% power to detect a 20% interaction eff ect between treatment and thrombolysis status-ie, a 20% absolute diff erence in the treatment eff ect between thrombolysis and non-thrombolysis strata with a twosided alpha of 0·10 and assuming a 4:1 ratio of thrombolysis to non-thrombolysis patients. Concurrently,
Inclusion criteria
• Acute ischaemic stroke.
• Age 18-83 years (participants must not have had their 84th birthday).
• National Institutes of Health stroke scale score of 6 or greater as assessed immediately before thrombolysis treatment if the patient was eligible for thrombolysis, or before randomisation for patients not eligible. • Start of albumin or placebo within 5 h of stroke onset and within 90 min of the start of thrombolysis with intravenous alteplase if that treatment was used.
• Signed and dated informed consent obtained.
Exclusion criteria
• An episode or exacerbation of congestive heart failure from any cause in the past 6 months. An episode of congestive heart failure was any heart failure that required a change in drug or diet, or hospital admission.
• Known valvular heart disease with congestive heart failure in the past 6 months.
• Known (or in the investigator's clinical judgment) existence of severe aortic stenosis or mitral stenosis.
• Cardiac surgery with thoracotomy (eg, coronary artery bypass graft or valve replacement surgery) in the past 6 months.
• Acute myocardial infarction in the past 6 months.
• Signs or symptoms of acute myocardial infarction, including electrocardiogram fi ndings, on admission.
• Elevated serum troponin concentration on admission (>0·1 μg/L).
• Suspicion of aortic dissection on admission.
• Acute arrhythmia (including any tachycardia or bradycardia) with haemodynamic instability on admission (systolic blood pressure <100 mm Hg).
• Findings on physical examination of any of the following abnormalities: jugular venous distention (jugular venous pressure >4 cm above the sternal angle); third heart sound; resting tachycardia (heart rate >100 beats per min) attributable to congestive heart failure; lower-extremity pitting oedema attributable to congestive heart failure; bilateral rales; defi nite evidence of pulmonary oedema, bilateral pleural eff usion, or pulmonary vascular redistribution on chest x-ray, if done.
• Acute or chronic lung disease needing supplemental chronic or intermittent oxygen therapy.
• Historical modifi ed Rankin scale score greater than 2.
Patients who lived in a nursing home or who were not fully independent for activities of daily living (eg, toileting, dressing, eating, cooking and preparing meals) immediately before the stroke were not eligible.
• In-patient stroke.
• Profound dehydration.
• Fever, defi ned as a core body temperature of more than 38·0°C.
• Serum creatinine concentrations of greater than 180 μmol/L.
• Severe chronic anaemia (haemoglobin <75 g/L).
• Evidence of intracranial haemorrhage (ie, intracerebral haematoma, intraventricular haemorrhage, subarachnoid haemorrhage, epidural haemorrhage, acute or chronic subdural haematoma) on the baseline CT or MRI scan.
• History of or known allergy to albumin.
• History of or known allergy to natural rubber latex.
• Pregnancy, breastfeeding, or positive pregnancy test.
Women of childbearing age should have had a negative pregnancy test before study drug was given.
• Concurrent participation in any other therapeutic clinical trial.
• Evidence of any other major life-threatening or serious medical disorder that would prevent completion of the study protocol, impair the assessment of outcome, or in which albumin treatment would be contraindicated or might cause harm to the patient.
Panel 1: Inclusion and exclusion criteria
we calculated that 980 individuals would be needed to test the primary hypothesis-ie, to detect a minimum eff ect size of 10 absolute percentage points in the primary outcome. We assumed that the control group's favourable primary outcome would be 40%, on the basis of the NINDS rt-PA Stroke Study 26 and the ALIAS part 1 trial. 27 We estimated the sample size on the basis of 85% power, a one-sided type 1 error probability of 0·025, and allowing for a group-sequential design for three interim analyses. 28 For overwhelming effi cacy, we adopted the alpha spending function approach, 29 and for futility, the beta spending function approach. 30 For both overwhelming effi cacy and futility, we used O'Brien-Fleming-type stopping guidelines, 28 and the binding boundaries and corrected pooled variance estimates. 31 We did analyses by intention to treat and derived the fi nal maximum sample size of 1092 to account for a proportion of about 5% of patients lost to follow-up with the approach of Friedman and colleagues. 32 Hence, we concluded that the 1100 individuals required to detect the interaction eff ect should provide suffi cient power for the primary analysis of the main treatment eff ect.
We did analyses with SAS (version 9.3). We used the generalised linear model with log link, with adjustment for baseline NIHSS score, thrombolysis status, and treatment-by-thrombolysis status interaction term. As was prespecifi ed in the trial's statistical analysis plan, we assessed the following baseline variables for possible confounders: age, race (black vs other), plasma glucose, systolic blood pressure, Alberta stroke program early computed tomography score (ASPECTS; 0-10), history of myocardial infarction, and time from symptom onset to randomisation. If the p values for these variables in the univariate analyses were less than 0·20, we included them in the secondary, covariate-adjusted analysis. We did a multivariate analysis of the treatment eff ect that included the following measures as covariates: baseline NIHSS, thrombolysis status, site patient volume (low, medium, or high), age, black race, plasma glucose, ASPECTS, and time from symptom onset to randomisation. The treatment eff ect was not changed as a result of this analysis.
This trial is registered with ClinicalTrials.gov, number NCT00235495.
Role of the funding source
The trial was funded by cooperative agreements from the US National Institutes of Health (National Institute of Neurological Disorders and Stroke). A representative of NINDS (CSM) participated in the study leadership committee and contributed to design decisions and to the interpretation and writing of the manuscript. Baxter Healthcare provided funds to extend the trial to Finland, but had no role in the design, undertaking, or interpretation Data are mean (SD), n (%), n/N (%), median (IQR), or mean (SD, min-max), unless otherwise indicated. NIHSS=National Institutes of Health stroke scale. ASPECTS=Alberta stroke program early computed tomography score. *Self-reported. †A 42-point scale that quantifi es neurological defi cits in 11 categories, with 0 as normal function without defi cits, and higher scores showing greater severities of defi cit. ‡Score uses computed tomography to assess ten regions of the brain; a score of 1 shows a normal region and 0 shows a region with signs of ischaemia; total scores range from 10 (no evidence of early ischaemia) to 0 (all ten regions of the aff ected hemisphere show early ischaemic changes). of the study. The sponsor of the study had no role in data collection or data analysis. The corresponding author had full access to all data in the study and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le. 841 individuals were randomly assigned to receive albumin (n=422) or saline (n=419). Half (47%) the participants were from hub sites or spoke sites of the NINDS-funded Neurological Emergencies Treatment Trials (NETT) network. At 3 months, 705 (83%) participants were alive and completed the 3-month follow-up. Table 1 shows baseline and treatment characteristics. Overall, the mean age of the subjects was 64·1 years (SD 12·9), and the median baseline NIHSS score was 11 (range 6-40). For all participants, mean time from stroke onset to start of study drug was 206 min (SD 52). 749 patients (89%) received some form of thrombolytic treatment (table 1) . Intravenous alteplase alone was given to 575 (68%) patients (table 1) . 137 (16%) patients received both intravenous alteplase and endovascular thrombolytic therapy (table 1). 37 (4%) patients received only endovascular therapy (table 1) . We did two pre-specifi ed interim analyses for overwhelming effi cacy or futility at enrolment of 275 participants and 550 participants. On Sept 10, 2012, after the DSMB requested and reviewed a third, unscheduled interim analysis (at enrolment of 732 participants), the Board recommended to the NINDS that enrolment be halted for futility and that all subjects then in the trial (n=841) be followed up only to 90 days.
Results
The proportion of individuals achieving a favourable primary outcome at 90 days (plus or minus 30 days) did not diff er signifi cantly between the albumin and saline groups (table 2) . Additionally, no signifi cant diff erence was shown in the primary outcome by treatment assignment in any of the predefi ned subgroups (table 3) . Other predefi ned outcomes assessed at 90 days-a composite outcome (mRS 0-1, NIHSS 0-1, or decrease in NIHSS from baseline by 10 or more points), mRS assessed by sliding dichotomy, Barthel index, EuroQol, stroke-specifi c quality of life, and the trailmaking tests-likewise showed no signifi cant diff erences by treatment assignment (table 2). Figure 2 shows the distribution of 90-day mRS scores in patients given albumin or saline.
We noted pulmonary oedema or congestive heart failure within 48 h in 13% of participants in the albumin group (table 4)-a rate that is consistent with that of patients given albumin in the ALIAS pilot trial 16 and the part 1 trial. 18 By contrast, this safety outcome arose in only 1% of patients in the saline group (table 4). This adverse event was typically of mild-to-moderate severity and was readily managed. Shortness of breath within 48 h, and atrial fi brillation within 48 h, were also more common in patients given albumin than in those given saline (table 4) . Although the rate of symptomatic or large intracranial haemorrhage within 24 h in both groups was as low or lower than rates reported in other major intravenous thrombolytic trials, 26, [36] [37] [38] patients given albumin nonetheless had a risk that was 2·4 times greater than patients given saline (table 4) . Correspondingly, 24 h CT scans read centrally showed a 2·8-times greater risk of larger (ie, type 2 33 ) parenchymal haemorrhages in the albumin group than in the saline group (table 4) . Other pre-specifi ed major safety outcomes showed no signifi cant diff erences by treatment (table 4) .
The rate of favourable primary outcome with albumin remained steady at 44-45% throughout the trial. However, our assumption that a favourable rate of 40% would be shown in the placebo group proved initially to be incorrect (fi gure 3); rather, the rate in patients given saline averaged 32% in the fi rst quarter of the trial, but rose steadily thereafter, so that an interaction of treatment-by-randomisation order was evident. At the fi rst prespecifi ed interim analysis (n=275) presented to the DSMB, there was an absolute diff erence of 14·5% in the rates of favourable outcome between the groups, with a relative benefi t of 1·48 favouring treatment with albumin (95% CI 1·12-1·97 adjusted for baseline NIHSS and thrombolysis status; one-sided p=0·0028). This fi nding suggests that the likelihood of favourable outcome was roughly 50% higher for patients in the albumin group. At the second pre-specifi ed interim analysis (n=550), the rate of favourable outcome had increased in the placebo group, whereas the rate in the albumin group remained steady (fi gure 3), for a relative benefi t of 1·21 favouring albumin (adjusted 95% CI 1·01-1·44; one-sided p=0·0176). However, at neither of these pre-specifi ed analyses did the diff erences cross the interim-analysis boundary for overwhelming effi cacy. 28 By the time the trial was stopped, we noted no diff erence by treatment assignment (fi gure 3). Table 5 shows the stopping boundaries and the statistics recorded in these interim analyses. A detailed analysis of outcome trends over time will be reported in a subsequent report.
Discussion
Despite convincing experimental evidence supporting ischaemic neuroprotection with high-dose albumin, [9] [10] [11] [12] [13] [14] [15] and despite an exploratory effi cacy analysis of a target population of individuals from ALIAS part 1 who would have satisfi ed revised eligibility criteria of the part 2 trial that showed a trend toward a favourable outcome with albumin treatment, 27 neither the primary nor secondary outcomes of the present defi nitive trial diff ered by treatment assignment (panel 2).
A limitation of this trial was that we were u nable to obtain complete 12-month assessments because of the Data are for n at risk/N of events. The safety sample consisted of the 830 patients who received at least 20% of the intended dose of study drug. ICH=intracranial haemorrhage. *Central reader. †Type 1 haemorrhage describes a blood clot not exceeding 30% of the infarcted area with some mild space-occupying eff ect. ‡Type 2 haemorrhage describes a dense blood clot or clots exceeding 30% of the infarct volume with substantial space-occupying eff ect. 33 Table 4 : Prespecifi ed safety events in the safety sample sponsor's decision not to provide funding for follow-up beyond the 3-month primary outcome assessment. Biologically, we restricted our study design to the estimated time window of treatment eff ect on the basis of preclinical fi ndings, 10 but we recognise that a 5 h window to treatment might still be too long. Furthermore, we did not control for reperfusion, either in application or timing, and because the only proven neuroprotectant strategy in human beings is the induction of prompt reperfusion, this might have aff ected our results.
The neutral outcomes of this and other major multicentre trials [41] [42] [43] [44] [45] [46] of neuroprotective strategies for acute ischaemic stroke raise the concern as to whether positive results in animal models of stroke can legitimately be translated to human beings. This question has elicited extensive discussion in the scientifi c literature. 
Systematic review
We searched PubMed for articles published before July 12, 2013, of the therapeutic use of albumin in stroke. We used the search string, "albumin [ti] AND brain AND (stroke OR ischemia OR hemorrhage)". The resulting reports were manually reviewed. Before our own clinical trials, custom-tailored haemodilution with albumin plus crystalloids was studied in a prospective single-centre study, and the investigators reported reduced 3-month mortality and increased functional independence. 39 Another study 40 was a retrospective review of the safety of high-dose albumin treatment in 30 participants treated within 24 h of stroke onset, and 60 controls. Albumin treatment was associated with a non-signifi cant trend towards cardiopulmonary adverse events. The only other studies identifi ed were our own trials-ALIAS pilot trial 16, 17 and ALIAS part 1 18, 27 -that formed the antecedents to the multicentre trial reported here. As of July 12, 2013, ClinicalTrials.gov listed three trials of albumin in cerebrovascular disorders: (1) a phase 2B study (NCT01684462) investigating the safety and effi cacy of 20% albumin 1·25 g/kg, given within 12 h of stroke onset, presently recruiting participants in Korea; (2) an inactive phase 2 trial of albumin for intracerebral haemorrhage, with use of MRI-imaging outcome markers (NCT00990509); and (3) a phase 1 dose-escalation trial, now terminated, of albumin for subarachnoid haemorrhage (NCT01747408).
Interpretation
This trial represents the translation of the concept of high-dose albumin neuroprotection from therapeutically successful preclinical studies in rodent models of focal cerebral ischaemia, through a pilot clinical trial and an antecedent multicentre clinical trial, in which both the albumin dose and the window of treatment were selected to be similar to those shown to be therapeutically effi cacious in the animal studies. The main safety event has been the consistent induction of mild-to-moderate pulmonary oedema, which can be successfully managed without serious consequences by fl uid restriction and diuretic therapy. The neutral primary and secondary effi cacy outcomes in the present trial were unexpected in view of suggestive signals of possible effi cacy emerging from the pilot trial 17 and from a target population of the antecedent part 1 trial. 27 Furthermore, interpretation of the present results is complicated by the fact that the outcome of patients given placebo improved steadily over time, such that signals of albumin's therapeutic effi cacy were present during the fi rst half of this trial, but had disappeared by its end.
the fi lament rather than by thrombolysis. The animals used were young and free of medical comorbidities, contrasting with human ischaemic stroke, which typically aff ects middle-aged and elderly patients who often have other medical disorders. Any or all of these diff erences might be relevant here.
The interpretation of this trial is challenged by the fact that participants in the placebo group had a steadily improving rate of favourable outcome, which did not occur in those in the albumin group. Thus, although the fi rst prespecifi ed interim analysis showed an apparent relative benefi t favouring albumin treatment, the eff ect had completely disappeared by the trial's end. Early fl uctuation in cumulative eff ect size over time has been reported for large cardiac trials, with a conclusion that continuation to the prespecifi ed fi xed sample size is essential. 51 We do not as yet have a satisfactory explanation for the steady improvement in rate of favourable outcome noted in the placebo, but not the albumin, group. We cannot exclude the possibility that ongoing improvements in general stroke care over the 3·5-year enrolment period might have aff ected the placebo group preferentially. With this hypothetical scenario, the stable rate of favourable outcome reported for the albumin group would be viewed as a so-called ceiling eff ect-ie, not sensitive to further improvements in stroke carewhereas the placebo group, whose favourable outcome was initially quite low, was susceptible to increases over time aff orded by steady improvements in standards of care and possibly by the increasing rate of use of intravenous alteplase observed over the course of the trial. In support of the notion of an albumin-related ceiling eff ect, fi ndings from an experimental study showed that albumin treatment had a signifi cant therapeutic eff ect after ischaemic stroke by augmenting the brain's collateral perfusion in a strain of mice with sparse brain collaterals, whereas the eff ect was not shown for a mouse strain having more abundant brain collateral circulation. 13 As in our previous trials, mild-to-moderate pulmonary oedema was the main drug-related adverse event, but was usually readily managed, and serious adverse events related to congestive heart failure were scarce. The fi ndings of signifi cantly greater symptomatic intracranial haemorrhage and of type 2 parenchymal haemorrhages by CT scan with albumin treatment were unanticipated and might relate to albumin's reported platelet antiaggregatory eff ect. [52] [53] [54] However, this adverse event did not seem to aff ect the rates of neurological deterioration or death, which were similar by treatment assignment.
Although our trial did not show that high doses of albumin improve the neurological or functional outcome of patients with acute ischaemic stroke, these fi ndings, or those of any well designed clinical trial, should not discourage future eff orts to identify eff ective strategies to protect the ischaemic brain, especially because an abundant preclinical literature continues to provide cogent proof-of-principle that this outcome might be possible.
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